Viridian Therapeutics, Inc. (VRDN) Discusses Positive Top Line Results From REVEAL-2 Phase III Trial in Chronic Thyroid Eye Disease - Slideshow

🇺🇸 Seeking Alpha (US) —

AI Summary

Viridian Therapeutics, Inc. reports positive results from the REVEAL-2 Phase III trial, which focuses on treating chronic thyroid eye disease. These findings suggest potential advancements in treatment options for patients with this condition.

Markets Deals Health Viridian Therapeutics Phase III chronic thyroid eye disease clinical trial healthcare investment

Read original source →